文献速递乳腺癌放疗

保乳术后同步整合补量中度大分割全乳放疗联合或不联合淋巴引流区照射的单中心前瞻性评估

Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery.
PubMed 文献 · Adv Radiat Oncol · 2023-05-21

该单中心前瞻性评估纳入2017年7月至2021年12月连续424例保乳术后接受同步整合补量中度大分割全乳放疗的患者(浸润性癌391例、导管原位癌33例),全乳40 Gy/15次/3周,瘤床同步补量至48 Gy;中位随访33个月,3年总生存98.2%、癌症特异生存99.1%、无病生存95.9%,任何局部区域复发风险0.6%,不良反应与美容效果良好。

要点

  • 全乳40 Gy/15次/3周,瘤床同步补量至48 Gy,依据START B与RTOG 1005/UK-IMPORT-HIGH。
  • 放疗完成时急性2级毒性13.3%,无3级急性毒性;3年随访内3级晚期效应仅见乳腺水肿需药物治疗。
  • 患者报告美容效果优良率各时间点均约96.5%–97.5%,3年任何局部区域复发风险0.6%。

核心结论

  • 同步整合补量中度大分割全乳放疗显示出非常有利的不良反应谱与美容效果/患者报告结局,3年局部区域控制极佳。
  • 该短程方案为患者提供显著舒适度并提升机构效率。

研究设计与样本

  • 单中心前瞻性评估,纳入2017年7月至2021年12月连续424例保乳术后接受同步整合补量中度大分割全乳放疗的患者,其中浸润性乳腺癌391例、导管原位癌33例。
  • 全乳40 Gy/15次/3周(依据START B试验),瘤床同步补量至48 Gy(依据RTOG 1005/UK-IMPORT-HIGH),采用三维适形放疗402例、调强放疗4例、容积旋转调强放疗18例。
  • 自2018年5月起纳入有淋巴引流区放疗指征的患者62例;患者平均年龄60岁(范围27–88岁)。
  • 记录基线参数与随访数据,包括治疗相关结局的客观评估与患者报告结局指标(PROMs)。

主要发现

  • 平均/中位随访29/33个月(范围2–60个月);放疗完成时急性毒性0、1、2、3级分别占25.0%、61.4%、13.3%、0%。
  • 6个月及1、2、3、4年随访时,2级晚期效应分别见于8.5%、6.0%、4.9%、2.2%、10.2%的患者,3级分别见于2.8%、1.1%、1.2%、0%、0%。
  • 唯一观察到的3级晚期效应为乳腺水肿需药物治疗。
  • 患者报告美容效果优良、一般、差在6个月及1、2、3、4年分别为97.2%/2.5%/0.4%、96.5%/3.1%/0.4%、97.4%/2.2%/0.4%、97.5%/2.5%/0%、96.5%/3.5%/0.0%。
  • 全部患者3年总生存、癌症特异生存、无病生存分别为98.2%、99.1%、95.9%;3年任何局部区域复发风险为0.6%;导管原位癌患者未见死亡或复发。

关键数值与推荐

  • 全乳放疗剂量40 Gy/15次/3周,瘤床同步补量至48 Gy,依据START B试验与RTOG 1005/UK-IMPORT-HIGH。
  • 放疗完成时急性2级毒性13.3%、3级0%;6个月至4年随访2级晚期效应4.9%–10.2%、3级0%–2.8%。
  • 患者报告美容效果优良率在6个月至4年随访为96.5%–97.5%。
  • 3年总生存98.2%、癌症特异生存99.1%、无病生存95.9%、任何局部区域复发风险0.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report treatment outcomes for patients who received adjuvant moderate hypofractionated whole-breast radiation therapy with simultaneous integrated boost (SIB-mhWBRT) after breast-conserving surgery. METHODS AND MATERIALS: SIB-mhWBRT for patients with breast cancer was introduced in our department in July 2017. This prospective evaluation includes 424 consecutive patients treated with SIB-mhWBRT for stage I-III invasive breast cancer (n = 391) and/or ductal carcinoma in situ (n = 33) until December 2021. SIB-mhWBRT was applied with 40 Gy in 15 daily fractions over 3 weeks according to the START B trial, with an SIB dose to the tumor bed of 48 Gy according to Radiation Therapy Oncology Group 1005/UK-IMPORT-HIGH, delivered as 3-dinemsional conformal radiation therapy (RT; n = 402), intensity modulated RT (n = 4), or volumetric modulated arc therapy (n = 18). The mean patient age was 60 years (range, 27-88). Since May 2018, patients with indications for lymphatic pathway RT were included (n = 62). Baseline parameters and follow-up data were recorded and reported, including objective assessment of treatment-related outcomes and subjective patient-reported outcome measures (PROMs). RESULTS: Mean/median follow-up was 29/33 months (range, 2-60). Acute toxicity grade 0, 1, 2, and 3 was observed in 25.0%, 61.4%, 13.3%, and 0%, respectively, at the completion of RT. Data of 281, 266, 243, 172, and 58 patients were available for 6-month and 1-, 2-, 3-, and 4-year follow-up, respectively. Grade 2 late effects were identified in 8.5%, 6.0%, 4.9%, 2.2%, and 10.2% and grade 3 in 2.8%, 1.1%, 1.2%, 0%, and 0% of patients at 6-month and 1-, 2-, 3-, and 4-year follow-up, respectively. Medical treatment of breast edema was the only grade 3 late effect observed. PROM cosmesis results were evaluated as excellent-good, fair, and poor in 97.2%, 2.5%, and 0.4%; 96.5%, 3.1%, and 0.4%; 97.4%, 2.2%, and 0.4%; 97.5%, 2.5%, and 0%; and 96.5%, 3.5%, and 0.0% at 6 months and 1, 2, 3, and 4 years post-RT, respectively. For all patients, the 3-year overall, cancer-specific, and disease-free survival rates were 98.2%, 99.1%, and 95.9%, respectively. Three-year risk of any locoregional recurrence was 0.6%. No mortality or relapse was observed in patients with ductal carcinoma in situ. CONCLUSIONS: SIB-mhWBRT demonstrated very favorable side effect profiles and cosmesis/PROMs. Three-year results demonstrate excellent locoregional control. This short-term regimen offers substantial patient comfort and improves institutional efficacy.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Unterkirhere O, Stenger-Weisser A, Kaever A, et al. Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery. Adv Radiat Oncol. 2023. PMID: 38047219. doi:10.1016/j.adro.2023.101270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。